Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNicholas Skertich
About this trial
This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
Eligibility criteria
Qualifiers
Adult 18 to 65 years of age
Body Mass Index >35 with comorbidity of Type 2 Diabetes and/or Hypertension and/or Hyperlipidemia and/or Obstructive Sleep Apnea OR Body Mass Index >40 with or without comorbidity
Undergoing primary sleeve gastrectomy
Disqualifiers
Prior metabolic and bariatric surgery
Prior use of GLP-1 agonist
Prior history of pancreatitis
Personal/family history of medullary thyroid cancer or MEN type 2
Trial design
Treatments tested in this trial
- Mounjaro
- Sleeve Gastrectomy
Treatment groups
42 Participants
are divided into 2 treatment groupsSponsors and collaborators
Nicholas Skertich
Lead sponsor
Rush University Medical Center
Sponsor institution
Source ClinicalTrials.gov